{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-23-000057","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2023-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.506637+00:00","generated_at":"2026-06-10T22:50:34.069010+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elicio Therapeutics receives $2.6M grant from GI Research Foundation for two cancer vaccines","bullets":["Grant awarded on Sept 7, 2023, adds to $2.8M received in Sept 2022 from GIRF.","Funds will advance ELI-007 (mutant BRAF-peptide) and ELI-008 (p53 hotspot mutation-peptide) vaccines.","Vaccines use Elicio's AMP lymph node-targeting platform; CMC, regulatory, and clinical prep underway.","BRAF V600E mutations seen in 40% melanoma, 10% colon, 2% lung; p53 mutations in ~30% solid tumors.","Non-dilutive funding supports IND planning and initial patient clinical assessment."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-23-000057","json":"https://secwatch.observer/filing/0001601485-23-000057.json","markdown":"https://secwatch.observer/filing/0001601485-23-000057.md","text":"https://secwatch.observer/filing/0001601485-23-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148523000057/0001601485-23-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148523000057/angn-20230907.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:50:34.069010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}